Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Cardiovascular disease in women with breast cancer - a nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Are cancer patients better off if they participate in clinical trials? A mixed methods study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality from cardiovascular disease in women with breast cancer - a nationwide registry study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HER2-positiv metastatisk brystkræft

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: There is increasing concern about cardiovascular disease (CVD) after breast cancer (BC). The aim of this study was to estimate the prevalence of different types of CVD in women diagnosed with BC compared to cancer-free controls as well as the incidence of CVD after BC diagnosis.

METHODS: We performed a cohort study based on data from national registries covering the entire Danish population. We followed 16,505 cancer-naïve BC patients diagnosed from 2003 to 2007 5 years before and up to 10 years after BC diagnosis compared to 165,042 cancer-free controls.

RESULTS: We found that 15.6% of BC patients were registered with at least one CVD diagnosis in hospital records before BC diagnosis. Overall, BC patients and controls were similar with regard to CVD comorbidity before BC diagnosis. After BC diagnosis, the incidence of all CVD diagnoses combined was significantly higher in BC patients than controls up to approximately 6 years after the index date (BC diagnosis). After 10 years, 28% of both BC patients and controls (without any CVD diagnosis up to 5 years before the index date) had at least one CVD diagnosis according to hospital records. However, the incidence of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism remained higher in BC patients than controls during the entire 10-year follow-up period. After 10 years, 2.7% of BC patients compared to 2.5% of controls were diagnosed with heart failure, 2.7% of BC patients compared to 1.5% of controls were diagnosed with thrombophlebitis/thrombosis, and 1.5% of BC patients compared to 1.0% of controls were diagnosed with pulmonary heart disease according to hospital records. Furthermore, we found that the risk of heart failure and thrombophlebitis/thrombosis was higher after chemotherapy.

CONCLUSIONS: Focus on CVD in BC patients is important to ensure optimum treatment with regard to BC as well as possible CVD. Strategies to minimise and manage the increased risk of heart failure, thrombophlebitis/thrombosis and pulmonary heart disease including pulmonary embolism in BC patients are especially important.

OriginalsprogEngelsk
Artikelnummer1040
TidsskriftBMC Cancer
Vol/bind21
Udgave nummer1
Sider (fra-til)1040
ISSN1471-2407
DOI
StatusUdgivet - 18 sep. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 67834442